Lupin eyes acquisition in the US market

22 Oct 2014 Evaluate

In a bid to strengthen its footprint in overseas market, drug major Lupin is scouting for acquisition opportunities in the US market, especially in inhalers and injectables segments. The company continues to be on the lookout for meaningful targets, be it brands or technology companies, in inhalation, complex injectables and skin diseases segments.

Moreover, the Mumbai-based firm is aiming to grow at around 25 per cent in the world’s largest drug market. Further, the company remains the 5th largest and fastest growing top five generic players in the U.S. for the third year now.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

 

Lupin Share Price

2122.65 1.00 (0.05%)
29-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.55
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2122.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×